The market for Prader-Willi syndrome (PWS) therapeutics exceeded 700 million USD in 2025, with the United States serving as the primary driver of demand. Current clinical standards remain heavily reliant on growth hormone therapy, which, while effective for managing growth failure, leaves critical symptoms like hyperphagia and behavioral dysregulation largely unaddressed. This gap has catalyzed a surge in R&D activity, with numerous pharmaceutical firms racing to bring novel mechanisms of action to patients.

Key pipeline candidates currently under investigation include Harmony Biosciences' WAKIX and HBS-102, Aardvark Therapeutics’ ARD-101, and ConSynance Therapeutics’ CSTI-500. The recent FDA approval of VYKAT XR in March 2025 marked a significant milestone, providing a new option for hyperphagia management. However, the path to market remains complex; companies like Aardvark Therapeutics have faced regulatory hurdles, including a recent clinical hold on their late-stage trials. According to DelveInsight, the influx of new entrants is expected to heighten competition, potentially pressuring pricing strategies and forcing a re-evaluation of current standards of care as developers look to secure their position in an evolving 2036 forecast landscape.